ClinicalTrials.gg
CompletedNCT05104892Updated Mar 7, 2024

Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe Asthma

A Phase 2 interventional study of Rilzabrutinib and placebo in Asthma, sponsored by Sanofi. Completed at 51 sites in 13 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-03-07.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
196
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies in Asthma by Sanofi — 3 open to participants now, 5 under way, 1 of them phase 3. Asthma · Sanofi.

Enrollment
26th of 31
196 · median 450
Started
2021
with 3 others
Phase 2
11 of 37
1 open now
Registered
27th of 37
by date

Among the 37 studies in Asthma by Sanofi, this one is the 26th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2021, is one of 11 in phase 2, and was the 27th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 37 studies in Asthma by Sanofi are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Asthma by Sanofi, or all of them as a file.
02

Study summary

This is a parallel, treatment, Phase 2, double-blind, 2 arm, 12-week Proof of Concept (PoC) study with 2 staggered cohorts (2 arms in each cohort) that is designed to assess the efficacy, safety, and tolerability of rilzabrutinib in adult participants (aged 18-70 years) with moderate-to-severe asthma who are not well controlled on ICS/LABA therapy. Study treatment includes investigational medicinal product (IMP) (rilzabrutinib or placebo) added-on to a background therapy of ICS/LABA (fluticasone/salmeterol [non-investigational medicinal product], standardized at screening). Background therapy of ICS/LABA will be withdrawn during the 12week randomized treatment period and resumed at the end of the IMP treatment period, as outlined below:

  • Screening period (4 weeks)
  • Randomized IMP treatment period (12 weeks ± 3 days)

    • Background therapy stabilization phase (4 weeks)
    • Background therapy withdrawal phase (4-5 weeks)
    • No background therapy phase (3-4 weeks)
  • Post IMP treatment safety follow-up period (4 weeks ± 3 days)
Read the detailed description

The total study duration per participant is expected to be up to 20 weeks: up to 4 weeks screening, 12 weeks on-treatment double-blind period, and 4-week post-IMP treatment follow up.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A physician diagnosis of asthma for at least 12 months based on the Global Initiative for Asthma (GINA) 2018,2019, 2020 Guidelines.
  • Participants with existing treatment with at least moderate to high doses of ICS therapy in combination with a LABA as second controller for at least 3 months with a stable dose ≥1 month prior to Visit 1.
  • Participants with prebronchodilator >40% of predicted normal at Visit 1/Screening. Prebronchodilator FEV1 ≥50% of predicted normal at Visit 2/Baseline.
  • Participants with reversibility of at least 12% and 200 mL in FEV1 15 to 30 minutes after administration of 2 to 4 puffs (200-400 mcg) of albuterol/salbutamol or levalbuterol/levosalbutamol during screening or documented history of a reversibility test that meets this criterion within 5 years prior to Visit 1 or documented positive response to methacholine challenge (a decrease in FEV by 20% [PC20] of \<8mg/mL) within 5 years prior to Visit 1/Screening is considered acceptable to meet this inclusion criterion.
  • Participants must have experienced, within 2 years prior to Visit 1, any of the following asthma exacerbation events at least once: Treatment with a systemic (oral or parenteral) for worsening asthma OR Hospitalization or emergency medical care visit for worsening asthma.
  • (BMI) ≥17.5 and ≤40 kg/m2
  • All use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Participants must have completed COVID-19 vaccination per current regional health authority recommendations prior to screening.

Exclusion criteria

Exclusion Criteria:

  • History of serious infections requiring intravenous therapy with the potential for recurrence (as judged by Site Investigator), with less than 4 weeks interval between resolution of serious infection and first dose of study drug, or currently active moderate-to-severe infection at Screening (Grade 2 or higher).
  • Chronic lung disease (for example, [COPD], or idiopathic pulmonary fibrosis [IPF]) which may impair lung function, or another diagnosed pulmonary or systemic disease associated with elevated peripheral eosinophil counts, for e.g. eosinophilic granulomatosis with polyangiitis.
  • History of life-threatening asthma (i.e., severe exacerbation that requires intubation).
  • Participants with any of the following events within the 4 weeks prior to their Screening Visit 1 or during the screening period: Treatment with 1 or more systemic (oral and/or parenteral) bursts for worsening asthma OR Hospitalization or emergency medical care visit for worsening asthma
  • Asthma Control Questionnaire 5-question version (ACQ-5) score \<1.25 or >3.0 at V2/randomization. During the screening period an ACQ-5 of up to ≤4 is acceptable.
  • Current smoker or cessation of smoking within the 6 months prior to Visit 1.
  • Previous smoker with a smoking history >10 pack-years.
  • Current or chronic history of liver disease.
  • Known hepatic or biliary abnormalities, e.g. moderate or severe hepatic impairment, such as B or C
  • Symptomatic herpes zoster within 3 months prior to screening.
  • nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude adequate rilzabrutinib/placebo absorption.
  • Conditions that may predispose the participant to excessive bleeding
  • History of solid organ transplant.
  • A history of of any type within 5 years before Day 1, other than surgically excised non-melanoma skin cancers or in situ cervical cancer.
  • Is not up-to-date with recommended vaccinations per local guidelines.
  • Anti-immunoglobulin E (IgE) therapy (e.g., omalizumab [Xolair®]) within 130 days prior to Visit 1 or any other biologic therapy (including anti-IL4/4R or IL-5/5R monoclonal antibodies [mAb]) or systemic (e.g., methotrexate) to treat inflammatory disease or disease (e.g., rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis) and other diseases, within 2 months or 5 half-lives prior to Visit 1, whichever is longer.
  • Use of inhalers other than ICSs, LABAs, and short-acting beta agonists (no long-acting muscarinic antagonists (LAMAs) or mucolytics) and leukotriene receptor antagonists (montelukast, zafirkulast) during the study period.
  • Participants who have received bronchial thermoplasty within 2 years prior to Visit 1 or plan to begin therapy during the screening period or the randomized treatment period.
  • Use of proton pump inhibitor drugs such as omeprazole and esomeprazole within 3 days of Day 1.
  • Use of known systemic strong-to-moderate inducers or inhibitors of within 14 days or 5 half-lives (whichever is longer) of Study Day 1 and until the end of the active treatment period.
  • except Bacille Calmette Guerinn-vaccination within 28 days prior to Day 1 or plans to receive one during the trial; Calmette Guerin-vaccination within 12 months prior to Screening.
  • COVID-19 vaccine within 14 days prior to Study Day 1.
  • Previous use of a Bruton tyrosine kinase (BTK) inhibitor.
  • Has received any drug (or is currently using an investigational device) within the 30 days before Day 1, or at least 5 times the respective elimination half-life time (whichever is longer).
  • (ECG) findings of corrected for heart rate (QTc) >450 msec (males) or >470 msec (females), poorly controlled atrial fibrillation (i.e., symptomatic patients or a ventricular rate above 100 beats/min on ECG), or other cardiovascular abnormalities.
  • Active COVID-19 infection as documented by a positive COVID-19 molecular test.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
196 participants (actual)

Study arms

  • Experimental
    Rilzabrutinib

    Rilzabrutinib BID or TID and ICS/LABA

    Drug: Rilzabrutinib

  • Placebo comparator
    Placebo

    Placebo and ICS/LABA

    Drug: placebo

Interventions

  • Pharmaceutical form: Tablet Route of administration: Oral

    Also known as: PRN1008/SAR444671

  • Drugplacebo

    Pharmaceutical form: Tablet Route of administration: Oral

06

What researchers measure

Primary outcomes

  1. Proportion of participants with an LOAC event during the treatment period

    Loss of Asthma Control (LOAC) event is defined as any of the following: * A 30% or greater reduction from baseline in morning peak expiratory flow (PEF) on 2 consecutive days * ≥6 additional reliever puffs of salbutamol/albuterol or levosalbutamol/levalbuterol in a 24-hour period (compared to baseline) on 2 consecutive days * Increase in ICS ≥4 times the last prescribed ICS dose (or ≥50% of the prescribed ICS dose at V2 if background therapy withdrawal completed) * Requiring use of systemic (oral and/or parenteral) steroid treatment * Requiring hospitalization or emergency room visit for asthma exacerbation

    Time frame: Until Week 12

Secondary outcomes

  1. Pre-bronchodilator FEV1 (Forced expiratory volume in one second) change from baseline to EOT (end of treatment)

    Time frame: From baseline to Week 12

  2. Post-bronchodilator FEV1 change from baseline to EOT

    Time frame: From baseline to Week 12

  3. The absolute change in the percent predicted FEV1 from baseline to EOT (pre- and post-bronchodilator)

    Time frame: From baseline to Week 12

  4. Change from baseline in pre- and post-bronchodilator FEV1 and forced vital capacity [FVC] at each spirometry endpoint

    Time frame: From baseline until Week 12

  5. Change from baseline in peak expiratory flow [PEF] and forced expiratory flow [FEF] 25-75% at each spirometry endpoint

    Time frame: From baseline until Week 12

  6. Asthma Control Questionnaire-5 (ACQ-5) score change from baseline at EOT and at each assessment time point

    The ACQ-5 is a questionnaire that measures the adequacy of asthma control and any changes in asthma control that may occur spontaneously or as a result of treatment. The ACQ-5 has five questions on the asthma symptoms and patients are asked to recall how their asthma has been during the previous week and to respond on a 7-point scale for each question (0 = no impairment, 6 = maximum impairment). The ACQ-5 score is the mean of the 5 questions and, therefore, between 0 (totally controlled) and 6 (severely uncontrolled). A high score indicates low asthma control.

    Time frame: From baseline until Week 12

  7. Asthma Quality of Life Questionnaire with Standardized Activities (AQLQ[S]) Self-administered score change from baseline at EOT and at each assessment time point

    The AQLQ(S) was designed as a self-administered patient reported outcome to measure the functional impairments that are most troublesome to adolescents and adults ≥12 years of age as a result of their asthma. The instrument is comprised of 32 items, each rated on a 7-point Likert scales from 1 to 7. Higher scores indicate better quality of life.

    Time frame: From baseline until Week 12

  8. Change in Asthma Daytime Symptom Diary (ADSD) and Asthma Nighttime Symptom Diary (ANSD) scores from baseline to EOT and each week

    ADSD and ANSD assess asthma severity based on patient self-report of asthma core symptoms, i.e., difficulty of breathing; wheezing; shortness of breath; chest tightness; chest pain; and cough. Both the ADSD and ANSD are composed of 6 items rated using an 11-point numerical rating scale (NRS) that ranges from 0 = None to 10 = As bad as you can imagine. The participants will record their daytime and nighttime asthma symptoms in an electronic diary, once in the evening and once in the morning, respectively.

    Time frame: From baseline until Week 12

  9. Plasma pharmacokinetic (PK) concentrations of rilzabrutinib in participants with asthma

    Time frame: Until Week 16

  10. Participants with Treatment Emergent Adverse Events

    Time frame: Until Week 16

  11. Change in numbers of inhalations/day of albuterol or levalbuterol for symptom relief from baseline to EOT and each week

    Time frame: From baseline until Week 12

07

Study locations

51 sites
  • Investigational Site Number : 0320004
    Berazategui, Buenos Aires CP 1884, Argentina
  • Investigational Site Number : 0320006
    Caba, Buenos Aires C1122AAK, Argentina
  • Investigational Site Number : 0320003
    Caba, Buenos Aires C1425FVH, Argentina
  • Investigational Site Number : 0320001
    Buenos Aires, C1121ABE, Argentina
  • Investigational Site Number : 0320005
    Ciudad Autonoma Buenos Aires, C1414AIF, Argentina
  • Investigational Site Number : 0320002
    Ciudad Autonoma Buenos Aires, C1425BEN, Argentina
  • Investigational Site Number : 1000004
    Kozloduy, 3320, Bulgaria
  • Investigational Site Number : 1000001
    Ruse, 7002, Bulgaria
  • Investigational Site Number : 1000003
    Sevlievo, 5400, Bulgaria
  • Investigational Site Number : 1000002
    Sofia, 1612, Bulgaria
  • Investigational Site Number : 1240006
    Vancouver, British Columbia V5Z 1M9, Canada
  • Investigational Site Number : 1240005
    Waterloo, Ontario N2J 1C4, Canada
  • Investigational Site Number : 1520005
    Curicó, Maule 3341643, Chile
  • Investigational Site Number : 1520002
    Talca, Maule, Chile
  • Investigational Site Number : 1520007
    Santaigo, Reg Metropolitana De Santiago 8241470, Chile
  • Investigational Site Number : 1520001
    Santiago, Reg Metropolitana De Santiago 7500692, Chile
  • Investigational Site Number : 1520004
    Santiago, Reg Metropolitana De Santiago 7500698, Chile
  • Investigational Site Number : 1520003
    Santiago, Reg Metropolitana De Santiago 8910131, Chile
  • Investigational Site Number : 1520006
    Quillota, Valparaíso 2260877, Chile
  • Investigational Site Number : 6420001
    Dusseldorf, 40225, Germany
  • Investigational Site Number : 3480001
    Edelény, 3780, Hungary
  • Investigational Site Number : 3480004
    Hajdunánás, 4080, Hungary
  • Investigational Site Number : 3480003
    Pécs, 7635, Hungary
  • Investigational Site Number : 4100007
    Daegu, Daegu-gwangyeoksi 705-717, Korea, Republic of
  • Investigational Site Number : 4100004
    Seoul, Seoul-teukbyeolsi 03312, Korea, Republic of
  • Investigational Site Number : 4100005
    Seoul, Seoul-teukbyeolsi 05030, Korea, Republic of
  • Investigational Site Number : 4100002
    Seoul, Seoul-teukbyeolsi 05505, Korea, Republic of
  • Investigational Site Number : 4100006
    Seoul, Seoul-teukbyeolsi 08308, Korea, Republic of
  • Investigational Site Number : 4100001
    Seoul, 06591, Korea, Republic of
  • Investigational Site Number : 4840001
    Guadalajara, Jalisco 44100, Mexico
  • Investigational Site Number : 4840002
    Monterrey, Nuevo León 64460, Mexico
  • Investigational Site Number : 4840005
    San Juan del Rio, Querétaro 76800, Mexico
  • Investigational Site Number : 4840003
    Durango, 34000, Mexico
  • Investigational Site Number : 4840004
    Veracruz, 91910, Mexico
  • Investigational Site Number : 6160007
    Lublin, Lubuskie 20-362, Poland
  • Investigational Site Number : 6160003
    Bialystok, Podlaskie 15-044, Poland
  • Investigational Site Number : 6160006
    Gdansk, Pomorskie 80-214, Poland
  • Investigational Site Number : 6160008
    Ostrowiec Swietokrzyski, Swietokrzyskie 27-400, Poland
  • Investigational Site Number : 6160009
    Poznan, Wielkopolskie 61-578, Poland
  • Investigational Site Number : 6160005
    Bialystok, 15010, Poland
  • Investigational Site Number : 6160002
    Krakow, 30-033, Poland
  • Investigational Site Number : 6160010
    Lodz, 90-752, Poland
  • Investigational Site Number : 6160001
    Lodz, 90141, Poland
  • Investigational Site Number : 6420002
    Cluj-Napoca, 400012, Romania
  • Investigational Site Number : 7240004
    Santander, Cantabria 39008, Spain
  • Investigational Site Number : 7240003
    Madrid / Madrid, Madrid, Comunidad De 28007, Spain
  • Investigational Site Number : 7240001
    Málaga, 29010, Spain
  • Investigational Site Number : 7920002
    Istanbul, 34303, Turkey
  • Investigational Site Number : 7920001
    Mersin, 33070, Turkey
  • Investigational Site Number : 8260002
    Cambridge, Cambridgeshire CB2 OQQ, United Kingdom
  • Investigational Site Number : 8260001
    Bradford, BD9 6RJ, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Feb 2024, 25 months.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 25 months is above that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2021
First posted
Nov 3, 2021
StartActual
Dec 12, 2021
Primary completionActual
Feb 6, 2024
CompletionActual
Feb 28, 2024
Last update
Mar 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05104892
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Nov 3, 2021
Start date
Dec 12, 2021
Primary completion
Feb 6, 2024
Completion
Feb 28, 2024
Last update
Mar 7, 2024

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rilzabrutinib

Start the discussion